Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The BreathID Hp Lab System is a non-invasive diagnostic medical device and test system developed by Meridian Bioscience for the detection of Helicobacter pylori (H. pylori) infection and the confirmation of its eradication. The system utilizes a 13C-urea breath test (UBT) methodology. Patients orally ingest a 75 mg 13C-urea tablet along with a citric acid solution (Citrica Powder). If H. pylori is present in the stomach, its urease enzyme metabolizes the 13C-urea into 13CO2 and ammonia. The 13CO2 is absorbed into the blood and subsequently exhaled. The BreathID Hp Lab System measures the 13CO2/12CO2 ratio in the exhaled breath using Molecular Correlation Spectroscopy (MCS) technology. It is designed for high-volume laboratory settings and is FDA-cleared for use in both adult and pediatric populations (ages 3–17).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on BreathID Hp Lab System (Exalenz Bioscience).